Lieff Cabraser partner Elizabeth J. Cabraser has been nominated for the 2018 Chambers USA Awards for Excellence in the category of Litigation: Business Trial Lawyers (Individuals).
The awards are based on Chambers USA’s internal research conducted for the 2018 edition of Chambers USA: America’s Leading Lawyers for Business and reflect lawyers’ pre-eminence in key practice areas. The selections also reflect notable achievements over the past 12 months, including outstanding work, impressive strategic growth and excellence in client service.
This year, the Chambers USA Awards ceremony dinner will be held on Thursday, May 24th at Cipriani 42nd Street, New York.
Congratulations to Elizabeth on this nomination!
About Chambers USA
Chambers has been ranking lawyers since 1990, and now covers 185 jurisdictions. The company ranks both lawyers and law firms based on research conducted by 170 full-time editors and researchers. Individual lawyers are ranked on the basis of their legal knowledge and experience, their ability, their effectiveness, and their client-service. These factors and considerations are judged by interviews with those active in the market and by assessing recent work done. Learn more at www.chambersandpartners.com
About Elizabeth Cabraser
A name partner and co-founder of Lieff Cabraser, Elizabeth Cabraser chairs the firm’s personal injury and environmental litigation practice groups. One of the nation’s leading class action litigators and possessing unparalleled expertise in complex civil litigation, she has served as court-appointed lead, co-lead, or class counsel in scores of federal multi-district and state coordinated proceedings. Today, she serves in court-appointed leadership positions in several of the nation’s highest profile civil cases, including a solo leadership role in the VW “Clean Diesel” Emissions case, as well as lead positions in the GM ignition switch defect and Takata defective airbag cases, and the recently-filed Fiat Chrysler Jeep Dodge diesel emissions fraud litigation, Generic Drugs Pricing antitrust litigation, and the National Prescription Opiates litigation.